Skip to main content
×
×
Home

Ketamine: stimulating antidepressant treatment?

  • Gin S. Malhi (a1), Yulisha Byrow (a2), Frederick Cassidy (a3), Andrea Cipriani (a4), Koen Demyttenaere (a5), Mark A. Frye (a6), Michael Gitlin (a7), Sidney H. Kennedy (a8), Terence A. Ketter (a9), Raymond W. Lam (a10), Rupert McShane (a11), Alex J. Mitchell (a12), Michael J. Ostacher (a13), Sakina J. Rizvi (a14), Michael E. Thase (a15) (a16) and Mauricio Tohen (a17)...
Summary

The appeal of ketamine – in promptly ameliorating depressive symptoms even in those with non-response – has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives – derived from evidence and clinical experience – and to consider strategies for future investigations.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Ketamine: stimulating antidepressant treatment?
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Ketamine: stimulating antidepressant treatment?
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Ketamine: stimulating antidepressant treatment?
      Available formats
      ×
Copyright
This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Corresponding author
Gin S. Malhi, Department of Psychiatry, University of Sydney, Sydney, Australia. Email: Gin.malhi@sydney.edu.au
Footnotes
Hide All

Declaration of interests

G.S.M. Grant/research support: National Health Medical Research Council, NSW Health, Ramsay Health, American Foundation for Suicide Prevention, AstraZeneca, Eli Lilly & Co, Organon, Pfizer, Servier, and Wyeth; has been a speaker for Abbott, AstraZeneca, Eli Lilly & Co, Janssen Cilag, Lundbeck, Pfizer, Ranbaxy, Servier, and Wyeth; consultant: AstraZeneca, Eli Lilly & Co, Janssen Cilag, Lundbeck, and Servier. M.A.F. Grant support: AssureRx, Janssen Research & Development, Mayo Foundation, Myriad, National Institute of Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), Pfizer. Consultant (Mayo): Janssen Research & Development, LLC, Mitsubishi Tanabe Pharma Corporation, Myriad Genetics, Neuralstem Inc., Sunovion, Supernus Pharmaceuticals, Teva Pharmaceuticals. CME/travel support: American Physician Institute, CME Outfitters. Financial interest/Mayo Clinic 2016: AssureRx. S.H.K. Grant/research support: Brain Canada, Bristol Meyer Squibb, CIHR, Janssen, Johnson & Johnson, Lundbeck, Ontario Brain Institute, Pfizer, Servier, St. Jude Medical, Sunovion. T.A.K. Grant/research support (through Stanford University): Sunovion Pharmaceuticals and Merck & Co., Inc.; consultant/advisory board bember: Allergan, Inc., Janssen Pharmaceuticals, Myriad Genetic Laboratories, Inc., and Sunovion Pharmaceuticals; lecture honoraria (not Speaker's Bureau payments): GlaxoSmithKline, and Sunovion Pharmaceuticals; royalties from American Psychiatric Publishing, Inc. Also, AstraZeneca Pharmaceuticals LP provided publication support to Parexel for preparation of a manuscript. Spouse employee and stockholder of Janssen Pharmaceuticals. R.W.L. Honoraria for speaking/advising/consulting, and/or received research funds: AstraZeneca, Brain Canada, Bristol Myers Squibb, Canadian Institutes of Health Research, Canadian Depression Research and Intervention Network, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Coast Capital Savings, Johnson and Johnson, Lundbeck, Lundbeck Institute, Pfizer, Servier, St. Jude Medical, Takeda University, Health Network Foundation, and Vancouver Coastal Health Research Institute. R.M. Investigator Janssen trials of esketamine; ‘paid-for’ ketamine clinic operated by Oxford Health NHS Foundation Trust - fees used to support the Trust. M.J.O. Consultant: Sunovion and Acadia Pharmaceuticals. Full-time employee of U.S. Department of Veterans Affairs. M.E.T. Advisory/Consultant: Alkermes, Allergan, AstraZeneca, Bristol-Myers Squibb Company, Cerecor inc., Eli Lilly & Co., Forest Laboratories, Gerson Lehrman Group, Fabre-Kramer Pharmaceuticals, Inc., GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante Inc., Merck and Co. Inc. (formerly Schering Plough and Organon), Moksha8, Naurex Inc., Neuronetics Inc., Novartis, Ortho-McNeil Pharmaceuticals (Johnson & Johnson; Janssen), Otsuka, Pamlab, L.L.C. (Nestle), Pfizer (formerly Wyeth Ayerst Pharmaceuticals), Shire US Inc., Sunovion Pharmaceuticals Inc., Trius Therapeutical Inc. and Takeda. Grant support: Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Forest Pharmaceuticals, Janssen, National Institute of Mental Health, and Otsuka Pharmaceuticals. Speakers Bureau: None since June, 2010. Equity Holdings: MedAvante, Inc. Royalties: American Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company, Inc. Spouse's employment: Peloton Advantage, which does business with Pfizer. M.T. Full-time employee at Lilly 1997 to 2008. Honoraria/consulted: Abbott, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Johnson & Johnson, Allergan, Otsuka, Merck, Sunovion, Forest, Geodon Richter Plc, Roche, Elan, Alkermes, Lundbeck, Teva, Pamlab, Minerva, Wyeth and Wiley Publishing. Spouse was full time-employee at Lilly 1998–2013.

Footnotes
References
Hide All
1 World Health Organization (WHO). The Global Burden of Disease 2004 Update. WHO, 2008. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf
2 Malhi, GS, Bassett, D, Boyce, P, Bryant, R, Fitzgerald, PB, Fritz, K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49: 1087–206.
3 Gaynes, BN, Warden, D, Trivedi, MH, Wisniewski, SR, Fava, M, Rush, AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009; 60: 1439–45.
4 Malhi, GS, Byrow, Y. Is treatment-resistant depression a useful concept? Evid Based Mental Health 2016; 19: 13.
5 Crown, WH, Finkelstein, S, Berndt, ER, Ling, D, Poret, AW, Rush, AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002; 63: 963–71.
6 Domino, EF. Taming the ketamine tiger. Anesthesiology 2010; 113: 678–86.
7 Sanacora, G, Schatzberg, AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 2015; 40: 259–67.
8 Li, JH, Vicknasingam, B, Cheung, YW, Zhou, W, Nurhidayat, AW, Jarlais, DC, et al. To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil 2011; 2: 1120.
9 Berman, RM, Cappiello, A, Anand, A, Oren, DA, Heninger, GR, Charney, DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351–4.
10 Zarate, CA, Singh, JB, Carlson, PJ, Brutsche, NE, Ameli, R, Luckenbaugh, DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856–64.
11 Duman, RS, Monteggia, LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116–27.
12 Caddy, C, Amit, BH, McCloud, TL, Rendell, JM, Furukawa, TA, McShane, R, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015; 9: CD01162.
13 McGirr, A, Berlim, MT, Bond, DJ, Fleck, MP, Yatham, LN, Lam, RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2015; 45: 693704.
14 Lee, EE, Della Selva, MP, Liu, A, Himelhoch, S. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 2015; 37: 178–84.
15 Murrough, JW, Perez, AM, Pillemer, S, Stern, J, Parides, MK, aan het Rot, M, et al. Rapid and longer-term antidepressant effects of repeated Ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74: 250–6.
16 Diamond, PR, Farmery, AD, Atkinson, S, Haldar, J, Williams, N, Cowen, PJ, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 2014; 28: 536–44.
17 Price, RB, Mathew, SJ. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs 2015; 29: 181–8.
18 Murrough, JW, Soleimani, L, DeWilde, KE, Collins, KA, Lapidus, KA, Iacoviello, BM, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med 2015; 45: 3571–80.
19 Soleimani, L, Welch, A, Murrough, JW. Does ketamine have rapid anti-suicidal ideation effects? Curr Treat Options Psych 2015; 2: 383–93.
20 McCloud, TL, Caddy, C, Jochim, J, Rendell, JM, Diamond, PR, Shuttleworth, C, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev 2015; 9: CD011611.
21 Diazgranados, N, Ibrahim, L, Brutsche, NE, Newberg, A, Kronstein, P, Khalife, S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793802.
22 Zarate, CA, Brutsche, NE, Ibrahim, L, Franco-Chaves, J, Diazgranados, N, Cravchik, A, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71: 939–46.
23 Schatzberg, AF. A word to the wise about ketamine. Am J Psychiatry 2014; 171: 262–4.
24 Liao, Y, Tang, J, Ma, M, Wu, Z, Yang, M, Wang, X, et al. Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain 2010; 133: 2115–22.
25 Olney, JW, Labruyere, J, Wang, G, Wozniak, DF, Price, MT, Sesma, MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991; 254: 1515–8.
26 Wan, L-B, Levitch, CF, Perez, AM, Brallier, JW, Iosifescu, DV, Chang, LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry 2015; 76: 247–52.
27 Niesters, M, Martini, C, Dahan, A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol 2014; 77: 357367.
28 Majewski-Tiedeken, CR, Rabin, CR, Siegel, SJ. Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains. Drug Alcohol Depend 2008; 92: 217–27.
29 Rush, JA. Ketamine for treatment-resistant depression: ready or not for clinical use? Am J Psychiatry 2013; 170: 1079–81.
30 Moore, JW, Cambridge, VC, Morgan, H, Giorlando, F, Adapa, R, Fletcher, PC. Time, action and psychosis: using subjective time to investigate the effects of ketamine on sense of agency. Neuropsychologia 2013; 51: 377–84.
31 Lapidus, KAB, Levitch, CF, Perez, AM, Brallier, JW, Parides, MK, Soleimani, L, et al. A randomized controlled trial of Intranasal Ketamine in major depressive disorder. Biol Psychiatry 2014; 76: 970–6.
32 Schoevers, RA, Chaves, TV, Balukova, SM, aan het Rot, M, Kortekaas, R. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry 2016; 208: 108–13.
33 Rasmussen, KG, Lineberry, TW, Galardy, CW, Kung, S, Lapid, MI, Palmer, BA, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 2013; 27: 444–50.
34 Frye, MA, Blier, P, Tye, SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol 2015; 35: 334–6.
35 Kaufman, KR. Ethical considerations in placebo-controlled randomized clinical trials. Br J Psychiatry Open 2015; 1: e34.
36 Schak, KM, Vande Voort, JL, Johnson, EK, Kung, S, Leung, JG, Rasmussen, KG, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry 2016; 173: 215–8.
37 Li, CT, Chen, MH, Lin, WC, Hong, CJ, Yang, BH, Liu, RS, et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp 2016; 37: 1080–90.
38 Harraz, MM, Tyagi, R, Cortés, P, Snyder, SH. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psychiatry 2016; 21: 313–9.
39 Preskorn, S, Macaluso, M, Mehra, DO, Zammit, G, Moskal, JR, Burch, RM, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 2015; 21: 140–9.
40 Newport, DJ, Carpenter, LL, McDonald, WM, Potash, JB, Tohen, M, Nemeroff, CB, et al. APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172: 950–66.
41 Malhi, GS, Lingford-Hughes, AR, Young, AH. Antidepressant treatment response: ‘I want it all, and I want it now’ Br J Psychiatry 2016; 208: 101103.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Open
  • ISSN: -
  • EISSN: 2056-4724
  • URL: /core/journals/bjpsych-open
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 78 *
Loading metrics...

Abstract views

Total abstract views: 432 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 25th April 2018. This data will be updated every 24 hours.

Ketamine: stimulating antidepressant treatment?

  • Gin S. Malhi (a1), Yulisha Byrow (a2), Frederick Cassidy (a3), Andrea Cipriani (a4), Koen Demyttenaere (a5), Mark A. Frye (a6), Michael Gitlin (a7), Sidney H. Kennedy (a8), Terence A. Ketter (a9), Raymond W. Lam (a10), Rupert McShane (a11), Alex J. Mitchell (a12), Michael J. Ostacher (a13), Sakina J. Rizvi (a14), Michael E. Thase (a15) (a16) and Mauricio Tohen (a17)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *